Cover Image
市場調查報告書

PharmaPoint:克隆氏症 - 現在·未來市場參與企業

PharmaPoint: Crohn's Disease - Current and Future Players

出版商 GlobalData 商品編碼 299714
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:克隆氏症 - 現在·未來市場參與企業 PharmaPoint: Crohn's Disease - Current and Future Players
出版日期: 2014年01月31日 內容資訊: 英文 48 Pages
簡介

本報告提供全球的克隆氏症相關市場上現有企業及新加入企業相關分析,提供整體市場的未來展望和促進·阻礙因素,現在·未來的競爭趨勢,再加上主要企業簡介(營業內容,策略,業績,SWOT分析)等調查資料·考察,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

  • 分析的背景
  • 相關調查
  • 近日出版的相關調查

第3章 市場預測

  • 全球市場
    • 市場預測
    • 全球市場的促進·阻礙因素

第4章 現在·未來市場參與企業

  • 概要
  • 企業策略的趨勢
  • 企業簡介
    • Johnson & Johnson
    • AbbVie
    • UCB
    • Biogen Idec
    • 武田藥品工業
    • ChemoCentryx

第5章 附錄

圖表一覽

目錄
Product Code: GDHC1027FPR

GlobalData has released its pharma report, "PharmaPoint: Crohn's Disease - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Crohn's Disease Market. The report identifies and analyses the key companies shaping and driving the global Crohn's Disease market. The report provides insight into the competitive Crohn's Disease landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for Crohn's Disease
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of Crohn's Disease sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving Crohn's Disease market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global Crohn's Disease market landscape? Identify, understand and capitalize

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Market Outlook

  • 3.1. Global Markets
    • 3.1.1. Forecast
    • 3.1.2. Drivers and Barriers - Global Issues

4. Current and Future Players

  • 4.1. Overview
  • 4.2. Trends in Corporate Strategy
  • 4.3. Company Profiles
    • 4.3.1. Johnson & Johnson
    • 4.3.2. AbbVie
    • 4.3.3. UCB
    • 4.3.4. Biogen Idec
    • 4.3.5. Takeda
    • 4.3.6. ChemoCentryx

5. Appendix

  • 5.1. Bibliography
  • 5.2. Abbreviations
  • 5.3. Methodology
  • 5.4. Forecasting Methodology
    • 5.4.1. Diagnosed CD Patients
    • 5.4.2. Percent Drug-Treated Patients
    • 5.4.3. General Pricing Assumptions
    • 5.4.4. Generic Erosion
    • 5.4.5. Physicians and Specialists Included in This Study
  • 5.5. Primary Research - Prescriber Survey
  • 5.6. About the Authors
    • 5.6.1. Author/Reviewer
    • 5.6.2. Global Head of Healthcare
  • 5.7. About GlobalData
  • 5.8. Disclaimer

List of Tables

  • Table 1: Global Sales Forecasts ($) for CD, 2012-2022
  • Table 2: Global CD Market - Drivers and Barriers, 2012-2022
  • Table 3: Key Companies in the CD Market, 2013
  • Table 4: J&J's CD Portfolio Assessment, 2013
  • Table 5: J&J's CD SWOT Analysis, 2013
  • Table 6: AbbVie's CD Portfolio Assessment, 2013
  • Table 7: Abbott/AbbVie's CD SWOT Analysis, 2013
  • Table 8: UCB's CD Portfolio Assessment, 2013
  • Table 9: UCB's CD SWOT Analysis, 2013
  • Table 10: Biogen Idec's CD Portfolio Assessment, 2013
  • Table 11: Biogen Idec's CD SWOT Analysis, 2013
  • Table 12: Takeda's CD Portfolio Assessment, 2013
  • Table 13: Takeda's CD SWOT Analysis, 2013
  • Table 14: ChemoCentryx's CD Portfolio Assessment, 2013
  • Table 15: ChemoCentryx's CD SWOT Analysis, 2013
  • Table 16: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Global Sales for CD by Region, 2012-2022
  • Figure 2: Company Portfolio Gap Analysis in CD, 2012-2022
Back to Top